Business
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
ALAMEDA, Calif., July 24, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from t
About this update from Ipsen Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":327,"url":"https://media.zenfs.com/en/business-wire.com/398f97a43badf2e68c80398a46379368"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EkX1dbC1Atw2zhhObRR3HQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/398f97a43badf2e68c80398a46379368","width":960,"height":262},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QTq7czgDclYOgi.my3eW2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/398f97a43badf2e68c80398a46379368","width":1200,"height":327}},"lazy":false},{"type":"text","content":"– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"– CABOMETYX is the first and only systemic therapy to be approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy –","length":228,"tagName":"p","attribs":{}},{"type":"text","content":"ALAMEDA, Calif., July 24, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland.","length":755,"tagName":"p"},{"type":"text","content":""The availability of CABOMETYX in the European Union for patients with previously treated advanced neuroendocrine tumors is a significant milestone as there have been limited treatment advancements in the past decade, including very few option...